EFFECT OF ETHANOL EXTRACT OF *TETRACERA ALNIFOLIA* ON BLOOD GLUCOSE LEVEL AND GLUTATHIONE PEROXIDASE ACTIVITY IN STREPTOZOTOCIN INDUCED DIABETIC WISTAR RATS

BY

GRANT MORGAN EHIAIRINMWIAN

(BMS2000071)

DEPARTMENT OF MEDICAL BIOCHEMISTRY

SCHOOL OF BASIC MEDICAL SCIENCES

COLLEGE OF MEDICAL SCIENCES

UNIVERSITY OF BENIN

MARCH, 2025

EFFECT OF ETHANOL EXTRACT OF *TETRACERA ALNIFOLIA* ON BLOOD GLUCOSE LEVEL AND GLUTATHIONE PEROXIDASE ACTIVITY IN STREPTOZOTOCIN INDUCED DIABETIC WISTAR RATS

GRANT MORGAN EHIAIRINMWIAN

(BMS2000071)

A PROJECT SUBMITTED TO THE DEPARTMENT OF MEDICAL BIOCHEMISTRY, SCHOOL OF BASIC MEDICAL SCIENCES IN PARTIAL FULFILMENT OF THE REQUIREMENT FOR THE AWARD OF BACHELOR OF SCIENCE, B.Sc. (HONS) MEDICAL BIOCHEMISTRY, OF THE UNIVERSITY OF BENIN, BENIN CITY

MARCH, 2025

CERTIFICATION

We the undersigned hereby certify that GRANT MORGAN EHIAIRINMWIAN (BMS2000071) carried out this research in the Department of Medical biochemistry, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Benin city and thereby approve same as adequate in scope and quality for the award of Bachelor of Science Degree (B. Sc) in Medical biochemistry.

Signed

....

Prof. F. E. Olumese **(Date)**

(Project Supervisor)

....

Prof. F. E. Olumese **(Date)**

(Head of Department)

....

External Examiner **(Date)**

DEDICATION

This project is dedicated to Almighty God, the giver of life who has made it possible to complete my Bachelor of Science Degree (B. Sc) program in the Department of Medical biochemistry.

ACKNOWLEDGEMENTS

I am deeply grateful for the unwavering support and guidance I received throughout this project. First and foremost, I thank God Almighty for His unrelenting support and blessings, which sustained me throughout this journey. I extend my heartfelt appreciation to my supervisor Prof. F. E. Olumese for his invaluable guidance, expertise, and encouragement. Your support was instrumental in shaping this work. Also, to my parents Mr. and Mrs. Ehiairinmwian, my siblings and friends God bless you all, I am indeed grateful.

TABLE OF CONTENTS

ABSTRACT

Diabetes mellitus is characterized by chronic hyperglycemia–induced oxidative stress and electrolyte disturbances that exacerbate tissue injury and long-term complications. Traditional use of Tetracera alnifolia in Nigerian ethnomedicine suggests it may possess antidiabetic and antioxidant properties worthy of scientific evaluation. Adult Wistar rats were rendered diabetic via a single intraperitoneal injection of streptozotocin (65 mg/kg) and, after confirmation of hyperglycemia, randomly assigned to six groups (n=6): three groups received daily oral doses of T. alnifolia ethanol extract (200, 500, or 800 mg/kg) for 35 days; one group received glibenclamide (5 mg/kg); one remained untreated diabetic control; and one served as healthy control. Fasting blood glucose was measured on days 1, 7, 14, 21, 28, and 35. At study end, livers and pancreases were harvested for assessment of glutathione peroxidase (GPx) and glutathione reductase (GR) activities, respectively, and serum was analyzed for potassium levels. T. alnifolia extract induced a dose–dependent decline in fasting blood glucose, with the 800 mg/kg dose achieving values comparable to glibenclamide by day 35. Hepatic GPx activity, suppressed by diabetes (2.86 ± 0.38 U/g), was restored to 34.26 ± 0.62 U/g at 800 mg/kg (Table 4.1), exceeding the glibenclamide response (20.65 ± 0.01 U/g). Pancreatic GR activity rose from 2.42 ± 0.22 U/g in diabetic controls to 8.41 ± 0.26 U/g and 10.28 ± 1.28 U/g in the 800 mg/kg and glibenclamide groups, respectively (Table 4.2). Serum potassium, diminished by diabetes, was normalized across all extract doses. The ethanol extract of T. alnifolia exerts potent hypoglycemic, antioxidant, and electrolyte-stabilizing effects in STZ-induced diabetic rats, validating its traditional antidiabetic use. These findings support further molecular and histopathological studies to clarify its mechanisms and therapeutic potential.

CHAPTER ONE

INTRODUCTION

1.1 Background of the study

Diabetes is considered to be one of the most common chronic diseases worldwide. There is a growing scientific and public interest in connecting oxidative stress with a variety of pathological conditions including diabetes mellitus (DM) as well as other human diseases (Sharifi-Rad *et al*., 2020). Previous experimental and clinical studies report that oxidative stress plays a major role in the pathogenesis and development of complications of both types of Diabetes mellitus. Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from insufficient insulin secretion and/or insulin resistance (Leyane *et al*., 2022). The long-term complications of diabetes are largely driven by oxidative stress, a condition in which the production of reactive oxygen species (ROS) exceeds the capacity of the body's antioxidant defenses. On one hand, hyperglycemia induces free radicals; on the other hand, it impairs the endogenous antioxidant defense system in patients with diabetes. Endogenous antioxidant defense mechanisms include both enzymatic and non-enzymatic pathways (Eddaikra and Eddaikra, 2021), Common antioxidants include the vitamins A, C, and E, glutathione (GSH), and the enzymes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GRx). In particular, the activity of glutathione peroxidase (GPx) a key enzyme that catalyzes the reduction of hydrogen peroxide and lipid peroxides and is often diminished in diabetic conditions, thereby exacerbating cellular damage and contributing to the progression of diabetic complications (Shaparov, *et al*., 2021). Medicinal plants have long been used in traditional medicine for managing diabetes. Among these, *Tetracera alnifolia* a member of the *Dilleniaceae* family has been traditionally used for its antidiabetic properties. Recent *in vitro* and computational

investigations have revealed that ethanol extracts of T. alnifolia stem bark possess significant antiglycation and antioxidant activities (Ajao and Sadgrove, 2024). Studies have isolated bioactive compounds such as kaempferol, quercetin, and gallic acid from T. alnifolia, which were found to reduce fasting blood glucose levels and exhibit structural stability that correlates with their antiglycation effects (Arsenijević *et al*., 2024). Given that diminished GPx activity is implicated in the progression of diabetic complications, an agent that can restore or enhance GPx activity while simultaneously reducing hyperglycemia would be of considerable clinical interest.

1.2 Aim of study

The aim of this study was to evaluate the antidiabetic property of the ethanol extract of roots of *Tetracera alnifolia* in streptozotocin-induced diabetic Wistar rats by assessing its effect on blood glucose levels and glutathione peroxidase activity.

1.3 Objective of study

The objective of this study is:

1. To assess the anti-hyperglycemic efficacy of ethanol extract of roots of *Tetracera alnifolia* streptozotocin-induced diabetic Wistar rats;
2. To compare the anti-hyperglycemic efficacy of the extract with glibenclamide, a standard anti-diabetic drug; and to determine its effect on glutathione peroxidase activity.

1.4 Justification of study

This study is carried out as it explores a traditional medicinal plant, *Tetracera alnifolia*, for its potential to improve glycemic control and antioxidant status, offering a complementary approach to diabetes management.

CHAPTER TWO

LITERATURE REVIEW

2.1 DIABETES MELLITUS

Diabetes mellitus (DM) is widely recognized as one of the leading causes of death and disability worldwide. The prevalence of diabetes will rise from 6% to over 10% in the next decade (Lin *et al*., 2020). In 2000, the World Health Organization (WHO) recorded a total of 171 million people for all age groups worldwide (2.8% of the global population) who have diabetes (Murtaza *et al*., 2024), and the numbers are expected to rise to 366 million (4.4% of the global population) by 2030. Diabetes is a group of metabolic diseases characterized by high levels of blood sugar (hyperglycemia). It results from defects in insulin production and/or insulin action, and impaired function in the metabolism of carbohydrates, lipids and proteins which leads to long term health complications. In diabetic patients, long-term damage, dysfunction, and failure of different organs, (Zhao *et al*., 2023), especially the eyes (diabetic retinopathy), kidneys (diabetic nephropathy) nerves (diabetic neuropathy), heart (myocardial infarction), and blood vessels (atherosclerosis) are related to uncontrolled hyperglycemia. However, diabetic patients vary in their predisposition to the development of complications. The genetic hypothesis suggests that complications from diabetes are genetically predetermined as part of the diabetic syndrome, whereas the metabolic hypothesis suggests that complications such as cellular and vascular damage are the effects of long-term hyperglycemia. The Diabetes Control and Complications Trial (DCCT) convincingly showed that complications from diabetes can be delayed and reduced by maintaining tight glycemic control (Nathan and Lachin, 2024). Diabetes with its ever-increasing global prevalence has emerged as one of the most important and challenging health issues confronting the human population of the present world. The increase in the prevalence of diabetes in most regions across

the globe has been parallel to the rapid economic development, leading to urbanization and adoption of modern lifestyle habits (Luo and Wang, 2022). In the year 2019, the number of adult people aged 20–79 years with diabetes has been estimated to be about 463 million, which represents 9.3% of the total world adult population (Sun *et al*., 2022). By the year 2030, this number has been estimated to increase to 578 million, representing 10.2% of the total world adult population and further increase to 700 million by the year 2045, which represents 10.9% of the total world adult population (Saeedi *et al*., 2019). In the year 2019, the prevalence of diabetes among men and women has been estimated to be 9.6% and 9.0%, respectively, of the total respective gender world population (Berger and Zdzieblo, 2020). Furthermore, in the year 2019, approximately 4.2 million adult people aged 20–99 years died due to diabetes, and its associated complications and health expenditure on diabetes estimated to at least 760 billion USD, which represents 10% of the total spending on adults. Diabetes during pregnancy has been estimated to have affected more than 20 million live births (1 in 6 live births) in the year 2019.

2.1.1 Classification

DM is characterized by complex pathogenesis and varied presentation and any classification of this disorder, therefore, is arbitrary, but nevertheless useful, and is often influenced by the physiological conditions present at the time of assessment and diagnosis (Genuth *et al*., 2021). The classification currently used is based on both the etiology and the pathogenesis of disease and is useful in the clinical assessment of disease and for deciding the required therapy (Moe *et al*., 2023). According to this classification, diabetes can be divided into four main types or categories: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and diabetes caused or associated with certain specific conditions, pathologies, and/or disorders (figure 2.1) (Yameny, 2024).



Figure 2.1: Four types of diabetes mellitus (Yameny, 2024).

2.1.1.1 Type 1 diabetes mellitus

Type 1 diabetes mellitus (T1DM), also known as type 1A DM1ADM or as per the previous nomenclature as insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes, constitutes about 5–10% of all the cases of diabetes (Yameny, 2024). It is an autoimmune disorder characterized by T-cell-mediated destruction of pancreatic β-cells, which results in insulin deficiency and ultimately hyperglycemia. The pathogenesis of this autoimmunity, though not yet fully understood, has been found to be influenced by both genetic and environmental factors. (Ahamed *et al*., 2022). The rate of development of this pancreatic β-cell-specific autoimmunity and the disorder itself is rapid in most of the cases as in infants and children (juvenile onset) or

may be gradual as in adults (late onset) (Berger and Zdzieblo, 2020). The variability in the rate at which the immune-mediated destruction of the pancreatic β-cells occurs often defines the eventual progression of this disease (Roy *et al*., 2024). In some cases, children and adolescents, the β-cell destruction and subsequent failure occur suddenly, which can lead to diabetic ketoacidosis (DKA), often described as the first manifestation of the disease (Deligiorgi and Trafalis, 2023). In others, the disease progression is very slow with a mild increase in fasting blood glucose levels, which assumes a severe hyperglycemic form with or without ketoacidosis, only in the presence of physiological stress conditions such as severe infections or onset of other disorders. In some other cases, which include adults, β-cells may retain some degree of function to secrete only that quantity of insulin, which is only sufficient to prevent ketoacidosis for many years. However, due to progressive insulin deficiency, these individuals become insulin-dependent with the emergence of severe hyperglycemia and subsequent ketoacidosis. Despite the variable progression of this type of diabetes, the affected individuals in the beginning or in the middle or even in the later stages of their life become severely or absolutely insulin-deficient and become dependent on insulin treatment for their survival. This severe or absolute insulin deficiency irrespective of its occurrence at any age manifests itself as low or undetectable levels of plasma C-peptide (Le Pard, 2022). T1DM is an autoimmune disorder characterized by several immune markers, in particular autoantibodies. These autoantibodies are associated with the immune-mediated β-cell destruction, characteristic of this disease. The autoantibodies include glutamic acid decarboxylase autoantibodies (GADAs) such as GAD65, islet cell autoantibodies (ICAs) to β-cell cytoplasmic proteins such as autoantibodies to islet cell antigen 512 (ICA512), autoantibodies to the tyrosine phosphatases, IA-2 and IA-2α, insulin autoantibodies (Insulin autoantibodies), and autoantibodies to islet-specific zinc transporter isoform 8 (ZnT8) (R). At least one of these autoantibodies can be

used for the clinical diagnosis of this disease but usually more of these immune markers have been observed in approximately 85–90% of patients with new-onset T1DM Of these autoantibodies, (Welsch, 2023). GAD65 is the most important and is present in about 80% of all T1DM individuals at the time of diagnosis, followed by ICAs present in 69–90% and IA-2α found in 54–75% of all T1DM individuals at clinical presentation. The Insulin autoantibodies are important immune markers present in infants and young children who are prone to diabetes and its prevalence decreases as the age of onset of diabetes increases. The presence of Insulin autoantibodies in these individuals who have not been previously treated with insulin is an important indication of developing T1DM (Tatovic *et al*., 2023). Insulin autoantibodies are present in about 70% of all infants and young children at the time of diagnosis. The Insulin autoantibodies also play an important inhibitory role toward insulin function in patients on insulin therapy. Although not often clinically significant but nevertheless, this immune response has been observed with varying degrees of severity in at least 40% of patients on insulin treatment and therefore shows differential clinical manifestations (García, 2020). These autoantibodies mostly consist of polyclonal immunoglobulin G (IgG) antibodies and differ in their affinities and binding capacities toward insulin. Insulin autoantibodies can either be high insulin affinity/low insulin-binding capacity or low insulin affinity/high insulin-binding capacity. The low insulin affinity/high insulin-binding capacity insulin autoantibodies are responsible for clinical manifestations. At high titers, the binding of these antibodies to insulin prevents or delays its action and is responsible for characteristic hyperglycemia in the immediate postprandial period, which leads to significantly increased insulin requirements followed by unpredictable hypoglycemic episodes (postprandial hypoglycemia) observed later.

These autoantibodies assume more clinical and diagnostic importance in some cases, particularly adults, with late-onset of this disease where the destruction of the pancreatic β-cells occurs at a very slow rate and often the disease masquerades as in T2DM (Ramos-Casals *et al*., 2020). In such cases, these autoantibodies enable the correct diagnosis of this disorder as the T1DM, rather than the most common T2DM. This type of diabetes is often described as "Latent Autoimmune Diabetes in Adults (LADA)," also known as "slowly progressing insulin-dependent diabetes."

2.1.1.2 Type 2 diabetes mellitus

T2DM, also known as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes, as per the previous nomenclature, constitutes about 90–95% of all the cases of diabetes (Alam, 2021). This type of diabetes is characterized by two main insulin-related anomalies: insulin resistance and β-cell dysfunction. Insulin resistance results from disruption of various cellular pathways, which lead to a decreased response, or sensitivity of cells in the peripheral tissues, in particular the muscle, liver, and adipose tissue toward insulin (da Silva Rosa *et al*., 2020). In the early stages of the disease, decreased insulin sensitivity triggers β-cells hyperfunction to achieve a compensatory increase in insulin secretion to maintain normoglycemia. The higher levels of circulating insulin (hyperinsulinemia), thus, prevent hyperglycemia. However, gradually, the increased insulin secretion by β-cells is not able to compensate sufficiently for the decrease in insulin sensitivity. Moreover, β-cell function begins to decline and β-cell dysfunction eventually leads to insulin deficiency (Wajchenberg, 2007). As a result, normoglycemia can no longer be maintained and hyperglycemia develops. Although insulin levels are decreased, the secretion of insulin in most cases is sufficient to prevent the occurrence of DKA. But DKA may occur during severe stress conditions such as those associated with infections or other pathophysiological scenarios. DKA may also be precipitated by the use of certain drugs including sodium-glucose co-

transporter-2 (SGLT2) inhibitors, corticosteroids, and atypical antipsychotics (second-generation antipsychotic drugs). In absence of any severe physiological stress conditions, patients with T2DM often do not require any insulin therapy both at the time of disease onset and even after, throughout their lifetime (Kivimäki *et al*., 2023). T2DM progresses very slowly and asymptomatically with even mild hyperglycemia developing over years and as such remains largely undiagnosed until the appearance of classic symptoms associated with severe hyperglycemia such as weight loss, growth impairment, blurred vision, polyuria, and polydipsia in the advanced stages of the disease (Tareen and Tareen, 2022). The pathogenesis/etiology of this form of diabetes is complex and involves multiple known and unknown factors, which in a conclusive manner can be described as a combination of genetic (polygenic) predispositions and strong environmental influences. T2DM has been more frequently associated with increasing age, obesity, family history of diabetes, physical inactivity, and adoption of modern lifestyles: with prior GDM in women and with pathophysiological conditions such as hypertension and dyslipidemia. It occurs more frequently in individuals belonging to certain racial or ethnic groups including Native Americans (American Indians), Asian Americans, African Americans, Hispanic, and Latino (Berger and Zdzieblo, 2020). The frequent occurrence of T2DM in the mentioned racial or ethnic groups and its observed strong association with first-degree blood relations point strongly toward the role of genetic factors in the etiology of this disease (Goodarzi and Rotter, 2020), but these factors are complex and remain largely unspecified. However, unlike T1DM, no association of this disease has been found with genes involved in the immune response including autoimmunity and consequently there is no immune-mediated pancreatic β-cell destruction.

Obesity plays an important role in the homeostatic regulation of systemic glucose due to its influence on the development of insulin resistance through its effect on the sensitivity of tissues to

insulin and as such most but not all patients with T2DM are overweight or obese (Li *et al*., 2022). The increased body fat content, a characteristic of obesity, is such an important risk factor for T2DM that not only the total amount but also the distribution of body fat itself defines the development of insulin resistance and subsequently hyperglycemia. The increased abdominal fat or visceral obesity has been frequently associated with this type of diabetes in comparison to increased gluteal/subcutaneous fat or peripheral obesity (Alser *et al*., 2024). Due to its strong association with increased body fat content or obesity, the patients with T2DM often present with various cardiovascular risk factors such as hypertension and lipoprotein metabolic abnormalities characterized by elevated triglycerides and low levels of high-density lipoproteins (HDLs). Due to its lifelong duration and associated diverse metabolic derangements characteristic of hyperglycemia, T2DM, (Janssen, 2021), particularly in the middle and later decades, is frequently associated with the development of various microvascular and macrovascular complications.



Figure 2.2 Some of the main risk factors of type 2 diabetes mellitus (Janssen, 2021).

2.1.1.3 Gestational diabetes

Gestational diabetes resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 2–10% of all pregnancies and may improve or disappear after delivery. It is recommended that all pregnant women get tested starting around 24–28 weeks gestation. It is most often diagnosed in the second or third trimester because of the increase in insulin-antagonist hormone levels that occurs at this time. However, after pregnancy approximately 5–10% of women with gestational diabetes are found to have another form of diabetes, most commonly type 2. Gestational diabetes is fully treatable, but requires careful medical supervision throughout the pregnancy. Management may

include dietary changes, blood glucose monitoring, and in some cases, insulin may be required. Though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital heart and central nervous system abnormalities, and skeletal musclemal formations . Increased levels of insulin in a fetus's blood may inhibit fetal surfactant production and cause infant respiratory distress syndrome. A high blood bilirubin level may result from red blood cell destruction. In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment. Labor induction may be indicated with decreased placental function. A caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia. As the risk of developing type 2 diabetes is about 10 times higher in women with a history of gestational diabetes, postpartum screening may involve dietary, lifestyle, and drug interventions to prevent or delay its progression.

2.1.1.4 Drug- or chemical-induced diabetes

Several drugs and chemicals are known to induce diabetes. These agents induce diabetes either through the impairment of insulin production or secretion, which mainly results from the destruction of β-cells or through a decrease in the sensitivity of tissues to insulin, which causes insulin resistance. (Blahova *et al*., 2021). Diabetes resulting from the drug- or chemical-induced increase in insulin resistance occurs only in susceptible individuals. Furthermore, these agents may worsen or increase the severity of hyperglycemia in individuals with already existing overt diabetes (Khunti *et al*., 2021). The drugs and chemicals known to induce diabetes include glucocorticoids, diazoxide, thiazides, β_2-receptor agonists (salbutamol and ritodrine), nonselective β-adrenergic antagonists, dilantin, hormones including growth hormone (in very high doses), thyroid hormone (thyroxine/triiodothyronine), somatostatin, estradiol, levonorgestrel, and

glucagon (Banday *et al*., 2020). These also include γ-interferon, protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir), nicotinic acid, and β-cell toxins including streptozocin (streptozotocin), cyclosporine, rodenticide vacor and pentamidine, and several antipsychotics. Furthermore, immune checkpoint inhibitors, such as ipilimumab, nivolumab, and pembrolizumab, used in cancer immunotherapy for treatment of advanced-stage cancers, including head and neck cancer, renal cancer, urothelial cancers, non-small-cell lung carcinoma, and melanoma besides other cancers have been reported to induce new-onset T1DM, through immune-mediated β-islet cell dysfunction.

2.2 STREPTOZOTOCIN: MECHANISM OF ACTION

Streptozotocin or streptozocin (INN, USP) (STZ) is a naturally occurring alkylating antineoplastic agent that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals (Al-Musawi, 2020). It is used in medicine for treating certain cancers of the islets of Langerhans and used in medical research to produce an animal model for hyperglycemia and Alzheimer's in a large dose, as well as type 2 diabetes or type 1 diabetes with multiple low doses (Zhu, 2022). Streptozotocin (Fig. 2.3) inhibits insulin secretion and causes a state of insulin-dependent diabetes mellitus. Both effects can be attributed to its specific chemical properties, namely its alkylating potency. As with alloxan, its beta cell specificity is mainly the result of selective cellular uptake and accumulation.



Figure 2.3 Chemical structure of Streptozotocin (Diab *et al*., 2023).

2.3 PATHOPHYSIOLOGY ASSOCIATED WITH DIABETES

A patient with DM has the potential for hyperglycemia. The pathology of DM can be unclear since several factors can often contribute to the disease. Hyperglycemia alone can impair pancreatic beta-cell function and contributes to impaired insulin secretion. (Berger and Zdzieblo, 2020). Consequentially, there is a vicious cycle of hyperglycemia leading to an impaired metabolic state. Blood glucose levels above 180 mg/dL are often considered hyperglycemic in this context, though because of the variety of mechanisms, there is no clear cutoff point. Patients experience osmotic diuresis due to saturation of the glucose transporters in the nephron at higher blood glucose levels. Although the effect is variable, serum glucose levels above 250 mg/dL are likely to cause symptoms of polyuria and polydipsia. Insulin resistance is attributable to excess fatty acids and proinflammatory cytokines, which leads to impaired glucose transport and increases fat breakdown. (Vallon, 2020). Since there is an inadequate response or production of insulin, the body responds by inappropriately increasing glucagon, thus further contributing to hyperglycemia.

While insulin resistance is a component of T2DM, the full extent of the disease results when the patient has inadequate production of insulin to compensate for their insulin resistance (Berger and Zdzieblo, 2020). Chronic hyperglycemia also causes nonenzymatic glycation of proteins and lipids. The extent of this is measurable via the glycation hemoglobin (HbA1c) test. Glycation leads to damage in small blood vessels in the retina, kidney, and peripheral nerves. Higher glucose levels hasten the process. (Diab *et al*., 2023). This damage leads to the classic diabetic complications of diabetic retinopathy, nephropathy, and neuropathy and the preventable outcomes of blindness, dialysis, and amputation, respectively.

2.3.1 Treatment and management

Treatment and management of diabetes involve a multifaceted approach due to the complex physiology of the disease. Effective management requires a combination of lifestyle modifications, pharmacological interventions, and continuous patient education and engagement. Diabetic education plays a critical role, as patients with a clear understanding of their condition tend to have better outcomes. (Berger and Zdzieblo, 2020). Key components of lifestyle management include adhering to a carefully balanced diet with emphasis on carbohydrate and overall caloric restriction and engaging in regular physical activity (ideally more than 150 minutes per week). In addition, self-monitoring of blood glucose levels is essential for maintaining optimal glycemic control.

In clinical practice, the ideal target for blood glucose is typically maintained between 90 to 130 mg/dL, with glycated hemoglobin (HbA1c) levels kept below 7% (Kivimäki *et al*., 2023). However, while stringent glucose control is paramount, overly aggressive management can increase the risk of hypoglycemia, which may lead to serious adverse effects or even fatal outcomes. For type 1 diabetes mellitus (T1DM), which primarily results from the absence of insulin, the cornerstone of treatment is insulin replacement therapy. This can be achieved through

daily injections or the use of an insulin pump to mimic natural insulin secretion patterns. In contrast, treatment for type 2 diabetes mellitus (T2DM) often starts with lifestyle modifications such as dietary changes and increased physical activity especially in the early stages. (Li *et al*., 2022). When these measures are insufficient, pharmacological therapies are introduced to improve insulin sensitivity or stimulate the pancreas to secrete more insulin. Common drug classes include biguanides (with metformin as the first-line therapy), sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, glucagon-like peptide-1 agonists, dipeptidyl peptidase IV inhibitors (DPP-4 inhibitors), selective amylinomimetics, and sodium-glucose transporter-2 (SGLT-2) inhibitors. (Kivimäki *et al*., 2023). In some T2DM patients, especially in later stages of the disease when glucose management becomes more challenging, insulin therapy may also be required. In addition to these conventional treatments, medicinal plants have long been used in various traditional medical systems as an adjunct or alternative therapy for managing diabetes. Many cultures have relied on plant-based remedies, which are known to contain a range of bioactive compounds such as flavonoids, alkaloids, and terpenoids that can help lower blood glucose levels, enhance insulin sensitivity, and reduce oxidative stress. (Janseen, 2020). These natural treatments offer potential benefits with fewer side effects and have gained renewed interest as researchers continue to validate their efficacy through modern scientific methods.

2.4 ROLE OF OXIDATIVE STRESS IN DIABETIC COMPLICATIONS

The balance between the rate of free radical generation and elimination is important. Excess cellular radical generation can be harmful; however, if there is a significant increase in radical generation, or a decrease in radical elimination from the cell, oxidative cellular stress ensues. (Di Meo and Venditti, 2020). There is convincing experimental and clinical evidence that the generation of reactive oxygen species (ROS) increases in both types of diabetes and that the onset

of diabetes is closely associated with oxidative stress. Oxidative stress results from increased ROS and/or reactive nitrogen species (RNS). Examples of ROS include charged species such as superoxide and the hydroxyl radical, and uncharged species such as hydrogen peroxide and singlet oxygen. The possible sources of oxidative stress in diabetes might include auto-oxidation of glucose, shifts in redox balances, decreased tissue concentrations of low molecular weight antioxidants, such as reduced glutathione (GSH) and vitamin E, and impaired activities of antioxidant defense enzymes such as superoxide dismutase (SOD) and catalase (CAT) (Bhatti *et al*., 2022). ROS generated by high glucose is causally linked to elevated glucose and other metabolic abnormalities important to the development of diabetic complications. However, the exact mechanism by which oxidative stress may contribute to the development of diabetic complications is undetermined (Papachristoforou *et al*., 2020). In the past few decades, increasing evidence has connected oxidative stress to a variety of pathological conditions, including cancer, cardiovascular diseases (CVDs), chronic inflammatory disease, post-ischemic organ injury, diabetes mellitus, xenobiotic/drug toxicity, and rheumatoid arthritis (Taghavi and Moosavi-Movahedi, 2019). Over time, convincing evidence has established the role of free radicals and oxidative stress in the pathogenesis and development of complications from DM, including retinopathy, nephropathy, neuropathy, and accelerated coronary artery disease. Several studies have shown that elevated extra- and intra-cellular glucose concentrations result in oxidative stress which was reported both in experimental diabetes in animals and in diabetic patients. (Papachristoforou *et al*., 2020). The source of oxidative stress is a cascade of ROS leaking from the mitochondria. This process has been associated with the onset of type 1 diabetes (T1DM) via the apoptosis of pancreatic beta-cells, and the onset of type 2 diabetes (T2DM) via insulin resistance. The underlying mechanisms in the onset of diabetes are complex because

hyperglycemia could also be due to the cause-effect relationship of increased oxidative stress Biomarkers of increased oxidative stress, as measured by indices of lipid peroxidation and protein oxidation, increase in both T1DM, and T2DM (Papachristoforou *et al*., 2020).

The aetiology of oxidative stress in diabetes arises from a variety of mechanisms such as excessive oxygen radical production from auto-oxidation of glucose, glycated proteins, and glycation of antioxidative enzymes, which limit their capacity to detoxify oxygen radicals (Thakur *et al*., 2022). In addition to these mechanisms, two others have been suggested as being responsible for the generation of oxygen radicals in diabetes. First, Matough *et al*., (2022), demonstrated that high glucose levels could stimulate cytochrome P450-like activity by excessive nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) produced by glucose metabolism. Second, ketosis, a hallmark of T1DM in particular, could increase oxygen radical production in diabetic patients. Nowadays, diabetic micro- and macroangiopathy are considered to be poly aetiological multifactorial diseases (Taghavi and Moosavi-Movahedi, 2019). A number of studies have evaluated the role of oxidative stress in the etiology of microvascular and macrovascular complications of diabetes in the fasting state. Furthermore, there is growing evidence suggesting the role of hyperglycemia, hyperinsulinemia and dyslipidemia in diabetic patients, all of which have been implicated in the development of macro angiopathies, which possibly act upon their ability to induce oxidative stress, leading to endothelial dysfunction and atherosclerosis (Ali *et al*., 2023). Many studies have suggested that oxidative stress is a common pathogenic factor for the dysfunction of beta and endothelial cells (Thakur *et al*., 2022). Beta cell dysfunction results from prolonged exposure to high glucose, elevated free fatty acid (FFA) levels, or a combination of both. Beta cells are particularly sensitive to ROS because they are low in free-radical quenching (antioxidant) enzymes such as catalase (CAT), glutathione peroxidase (GPx) and superoxide

dismutase (SOD) (Berger and Zdzieblo, 2020). Therefore, the ability of oxidative stress to damage mitochondria and markedly blunt insulin secretion is not surprising. For example, it has been demonstrated that oxidative stress generated by short exposure of beta cell preparations to hydrogen peroxide (H_2O_2) increases the production of protein cyclin-dependent kinase inhibitor 1 (p21) and decreases insulin messenger ribonucleic acid (mRNA), cytosolic adenosine triphosphate (ATP), and calcium flux in cytosol and mitochondria (Vallon, 2020). In other studies, much experimental evidence has been accumulated to show that various types of vascular cells are able to produce ROS under hyperglycemic conditions. (Ali *et al*., 2023). The pathogenesis of diabetic nephropathy remains far from clear. An important role of oxidative stress for the development of nephropathy and neurological complications is suggested by experimental and clinical studies (Thakur *et al*., 2022).These studies establish a causal relationship between oxidative stress and diabetic nephropathy by observations that 1) lipid peroxides and 8-hydroxydeoxyguanosine, indices of oxidative tissue injury, increase in the kidneys of diabetic rats with albuminuria; 2) high glucose directly increases oxidative stress in glomerular mesangial cells and target cells of diabetic nephropathy; 3) oxidative stress induces mRNA expression of transforming growth factor beta 1 (TGF-β1) and fibronectin, which are the genes implicated in diabetic glomerular injury, and 4) inhibition of oxidative stress ameliorates all the manifestations associated with diabetic nephropathy (Zhu, 2022). Previous studies demonstrated that there is a close relationship between endothelial dysfunction and the development and progression of renal and cardiovascular pathology in patients with T1DM. The combined development of renal and cardiovascular complications is referred to as cardiorenal syndrome. (Ali *et al*., 2023). The causes of the development of cardiorenal syndrome in T1DM are poorly understood (Thakur *et al*., 2022). Previous studies suggest that endothelial dysfunction and the concomitant atherosclerotic process

may lead to simultaneous development and progression of renal and cardiac pathology, since endothelial dysfunction is already present at the early stages of T1DM (Zhu,2020)

2.4.1 Reactive oxygen species

Although molecular oxygen is required to sustain life, it can be toxic through the formation of ROS. Indeed, the unusual triplet state of the oxygen molecule, due to the presence of two unpaired electrons, confers a remarkable chemical stability, based on the Pauli Exclusion Principle, which forbids reactions between a singlet and a triplet molecule (Ali *et al*., 2023). Due to electron spin constraints, the oxygen molecule cannot readily react with organic substrates. Approximately 1–3% of oxygen consumed by the body is converted into ROS. Activation of oxygen can occur through two different mechanisms. The first mechanism of activation is absorption of sufficient energy to reverse the spin on one of the unpaired electrons, called a monovalent reduction. The biradical form of oxygen is in a triplet ground state because the electrons have parallel spins. If triplet oxygen absorbs sufficient energy to reverse the spin of one of its unpaired electrons, it will become singlet oxygen, in which the two electrons have opposite spins (Anlar, 2020). This activation overcomes the spin restriction and singlet oxygen can consequently participate in reactions involving the simultaneous transfer of two electrons (divalent reduction). The second mechanism of activation is by the stepwise monovalent reduction of oxygen to form superoxide (O_2), H_2O_2, hydroxyl radical (OH) and finally water. The first step in the reduction of oxygen forming superoxide is endothermic, but subsequent reductions are exothermic. Humans are exposed to many carcinogens, but the most significant may be the reactive species derived from the metabolism of oxygen and nitrogen known as ROS and RNS (Ahmed and Mohammed, 2020). On the one hand, the formation of ROS and RNS in the human body can cause oxidative damage to biological macromolecules, especially the plasma membrane, which may contribute to the

development of cancer, CVD, diabetes and other oxidative stress-mediated dysfunctions. On the other hand, ROS are known mediators of intracellular signaling cascades.

Even though ROS are generated under physiological conditions and are involved to some extent as signaling molecules and defense mechanisms as seen in phagocytosis, neutrophil function, macrophages and other cells of immune system (Ahmed and Mohammed, 2020), ROS are a heterogeneous group of molecules that are generated by mature myeloid cells during innate immune responses, and are also implicated in normal intracellular signaling. When phagocytes are activated, they produce ROS in amounts high enough to kill intruding bacteria. Also, shear-stress induced vasorelaxation and excess production of ROS may, on the other hand, lead to oxidative stress, loss of cell function, and ultimately to apoptosis or necrosis (Ali *et al*., 2023). ROS are produced by oxidative phosphorylation, NADPH, xanthine oxidase, the uncoupling of lipoxygenases, cytochrome P450 monooxygenases, and glucose autoxidation (Ali *et al*., 2023). Once formed, ROS deplete antioxidant defenses, rendering the affected cells and tissues more susceptible to oxidative damage by reacting with lipids in cellular membranes, nucleotides in DNA, sulphydryl groups in proteins, and cross-linking fragmentation of ribonucleoproteins, leading to changes in cellular structure and function (Ahmed and Mohammed, 2020). Levels of ROS are under tight control by the protective actions of antioxidant enzymes and nonenzymatic antioxidants in normal and healthy cells. However, in diabetes, excessive cellular levels of ROS are induced by hyperglycemia causing a major complication of DM (Thakur *et al*., 2022). Furthermore, in the case of diabetes or insulin resistance, a higher oxidative glucose metabolism itself increases mitochondrial production of $O2^{-\bullet}$ which will then be converted to $OH^{\bullet}$ and H_2O_2. Beyond glucose, ROS formation is also increased by FFAs, through its direct effect on mitochondria. It has been proposed that over-expression and activity of mitochondrial inner

membrane uncoupling proteins (UCPs) contribute to an increase in superoxide formation under diabetic conditions (R). In diabetes, NADPH oxidase is a major source of the generation of ROS. NADPH oxidase is located in the plasma membrane of various renal cell types, including mesangial and proximal tubular cells, vascular smooth muscle cells, endothelial cells, and fibroblasts. NADPH oxidase-dependent overproduction of ROS plays a key role in promoting hyperglycemia-induced oxidative stress. The NADPH oxidase increase oxidative stress and finally this increase results in the development of diabetic nephropathy in rats (Ali *et al*., 2023).



Figure 2.4: showing the role of ROS and their cause of oxidative stress as well as the functions of antioxidants in its prevention (Ali *et al*., 2023).

2.5 ANTIOXIDANT RESPONSE AGAINST OXYGEN RADICALS OF ENDOGENOUS OR EXOGENOUS SOURCES

Superoxide dismutase, catalase and glutathione peroxidase are antioxidant enzymes which do not only play fundamental but indispensable role in the antioxidant protective capacity of biological systems against free radical attack (Ali *et al*., 2023). The superoxide radical ($^{*}O_2$) or singlet oxygen radical ($^{1}O_2^{-}$) generated in tissues through metabolism or reactions in cells is catalytically converted to hydrogen peroxide (H_2O_2) and molecular oxygen (O_2) by superoxide dismutase (SOD) (Vallon, 2020). H_2O_2 when accumulated is toxic to body tissues or cells. Also, in the presence of Fe^{2+} it is converted to deleterious hydroxyl radical ($^{*}OH$) through Fenton reaction. In order to prevent this phenomenon, catalase (another antioxidant enzyme) which is abundant in the peroxisomes breaks down H_2O_2 into water and molecular oxygen, consequently curtailing free radical-induced damage (Ali *et al*., 2023). However, catalase is absent in the mitochondria, hence the reduction of H_2O_2 to water and lipid peroxides to their corresponding alcohols is carried out by Glutathione Peroxidase (GPx) (Zhu, 2022). This collective protective effort is termed first line antioxidant defense, and the antioxidants involved are referred to as first line defense antioxidants. The role and effectiveness of the first line defense antioxidants which basically include superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX) is therefore important and indispensable in the entire defense strategy of antioxidants, especially in reference to super oxide anion radical ($^{*}O_2$) which is perpetually generated in normal body metabolism through several processes.

2.5.1 Glutathione peroxidases (GPx)

Glutathione Peroxidase (GPx) is an important intracellular enzyme that breakdown hydrogen peroxides (H_2O_2) to water; and lipid peroxides to their corresponding alcohols mainly in the mitochondria and sometimes in the cytosol (Diallo et al., 2019). Most times, its activity depends on a micro nutrient co-factor known as selenium. For this reason, GP_X is often referred to as a selenocysteine peroxidase. The enzyme plays a more crucial role of inhibiting lipid peroxidation process, and therefore protects cells from oxidative stress. According to Morón and Cortázar (2019), there are at least eight GPx enzymes in human, GPx1–GPx8. The GPx 1–8 genes are mapped to chromosomes 3, 14, 5, 19, 6, 6, 1 and 5 respectively. Among the glutathione peroxidases, GPx1 is the most abundant selenoperoxidase and is present virtually in all cells. GPx2 is found much more in the gastrointestinal tract primarily in the intestine (Zhu, 2022). The kidney relative to other tissues is the primary location for GPx3, though; the enzyme is also present in extracellular fluids as a glycoprotein. Most forms of GPx are tetrameric in structure but GPx4 which is often regarded as phospholipid hydroperoxide is a monomer and differ in substrate specificity . This is because Gpx4 is the only GPx enzyme that breaks down phospholipid hydroperoxides. The enzyme also has a mitochondrial isoform that mediates the apoptotic response to oxidative stress and has a peroxidase independent structural role in sperm maturation. GPx5 from both humans and rodents and Rodent GPx6 differ from other glutathione peroxidases in that their activities are independent of Selenium (Berger and Zdzieblo, 2020). This invariably implies that these forms of GPx may not be able to effectively scavenge H_2O_2, a feature which is characteristic of the selenium-dependent glutathione peroxidases. The clinical importance of GPx has been underlined by a number of studies. Chabory *et al.,* (2020) postulated that individuals with lower GPx activity are predisposed to impaired antioxidant protection, which

leads to oxidative damage to membrane fatty acid s and functional proteins, and by inference, neurotoxic damage (Berger and Zdzieblo, 2020). Forgione and colleagues had previously hypothesized that GP_X1 deficiency directly induces an increase in vascular oxidative stress, with attendant endothelial dysfunction. Glutathione peroxidases, particularly GPx1 have also been implicated in the development and prevention of many common and complex diseases, including cancer and cardiovascular disease

2.6 MEDICINAL PLANTS

Medicinal plants offer a rich and diverse source of bioactive compounds that can play a crucial role in managing diabetes and its complications. Many of these plants exhibit both antiglycation and antioxidant properties, which are particularly beneficial in counteracting the long-term effects of chronic hyperglycemia (Anwar *et al*., 2021). Hyperglycemia leads to the non-enzymatic glycation of proteins, lipids, and nucleic acids, forming advanced glycation end-products (AGEs). These AGEs can disrupt cellular functions and contribute to oxidative stress a major underlying mechanism in the development of diabetic complications (Halim and Halim, 2019). In this context, medicinal plants that possess antiglycation properties can help prevent the formation of AGEs, while their antioxidant compounds scavenge free radicals, reduce oxidative damage, and improve overall cellular health. A number of phytochemicals such as flavonoids, phenolic acids, alkaloids, and terpenoids have been identified as responsible for these beneficial effects (Awuchi, 2020). For instance, compounds like quercetin, kaempferol, and their glycosides have been shown to not only reduce blood glucose levels but also inhibit the glycation process and neutralize reactive oxygen species (ROS). These dual actions are significant because some conventional hypoglycemic drugs, besides lowering blood glucose, also exhibit secondary antiglycation effects and enhance glucose uptake by tissues. (Anwar *et al*., 2021). A key player in glucose metabolism is the insulin-

responsive glucose transporter GLUT4. Under normal conditions, GLUT4 is sequestered in intracellular vesicles in muscle and adipose tissues. In response to insulin, a well-coordinated signaling cascade primarily mediated by proteins such as mitogen-activated protein kinases (MAPKs) triggers the translocation of GLUT4 to the plasma membrane. (Chukwuma *et al*., 2019). This process increases the uptake of glucose into cells, thereby lowering blood glucose levels. Certain medicinal plants have been found to modulate this pathway, enhancing GLUT4 translocation and function. By influencing these signaling pathways, these natural compounds can improve insulin sensitivity and overall glycemic control.

In addition to their effects on glycation and oxidative stress, many medicinal plants have been traditionally used to manage diabetes. Their long-standing use in ethnomedicine is supported by modern research that often confirms their hypoglycemic, anti-inflammatory, and even lipid-lowering effects. This integration of traditional knowledge with contemporary scientific validation paves the way for developing new, potentially safer, and more cost-effective antidiabetic therapies. (Chukwuma *et al*., 2019). Overall, medicinal plants endowed with antiglycation and antioxidant properties not only target high blood sugar levels but also mitigate the cellular damage caused by oxidative stress and glycation. Their ability to modulate key processes such as the insulin-induced GLUT4 translocation via MAPK signaling pathways makes them promising candidates for comprehensive diabetes management, offering an alternative or complementary approach to conventional pharmaceutical treatments (Thakur *et al*., 2022).

2.6.1 Overview of *Tetracera alnifolia*

Figure 2.65: *Tetracera alnifolia* (Horn, 2020).

Tetracera alnifolia is a species of flowering plant that belongs to the family *Dilleniaceae*, a family with a distinct yet relatively limited representation in Africa (Baldé, 2021). The taxonomic classification of *Tetracera alnifolia* can be outlined from the highest rank to the species level, providing insight into its evolutionary relationships, morphological characteristics, and geographical distribution. The taxonomic placement of *Tetracera alnifolia* within the *Dilleniaceae* is significant because this family, while diverse in other tropical regions, is much less common in Africa (Horn, 2020). In Nigeria, the presence of *T. alnifolia* represents an important component of the local flora, contributing to traditional medicinal practices. The restricted representation of the *Dilleniaceae* in Africa, limited to the genus *Tetracera*, suggests a unique evolutionary history. *Tetracera alnifolia* Willd is a perennial, evergreen big liana of the family *Dilleniaceae* which

commonly grows in the forests and other warm regions of sub-Saharan Africa including Guinea. Several parts of *T. alnifolia* have been traditionally used for treating infectious diseases (including sexual transmitted disease), skin diseases, and malaria in Guinean traditional medicine. This study is part of the program of the Institute for Research and Development of Medicinal and Food Plants of Guinea (IRDPMAG), whose goal is to rationalize the integration of phytotherapy into our health systems as recommended by the WHO. In this context, based on the ethnomedical investigations conducted by IRDPMAG, *Tetracera alnifolia* was selected to confirm some of its traditional uses in Guinea as well as to survey its chemical and biological properties. and adaptation to local ecological conditions.

2.6.2 Description

A line or multi-stemmed climber to 20 m high, or shrubby tree to about 8 m, or trailing in grassland; of savanna, thickets, forest margins, mangrove communities by coastal swamps, recorded from Senegal to West Cameroon aand also extending to Angola (Santos et al., 2020).The stem yields an abundant limpid sap which is potable. At one time the Bapanu of Gabon specially planted the plant in savanna regions against time of water-shortage. In Senegal the sap is dripped from a cut stem direct into the eye for 'clouding' (cataract) and eye-troubles. The same practice is followed in Ivory Coast for conjunctivitis (Oriakhi *et al*., 2022). In Gabon the sap is added to water and drunk for colic, and lactating mothers take the sap in which sweet tapioca has been macerated as a galactogogue (Santos et al., 2020). In Congo the sap is similarly given to mothers-in-milk. It is used to 'purify' both mother and child immediately after birth and is given to a baby with its first suckle and regularly to twins to strengthen them. The plant is held in Ivory Coast to have high therapeutic value in treatment of pain. Leafy twigs are ground up and mixed into a paste with palm-oil for application in cases of headache, intercostal and abdominal pain, rheumatism, etc., and a

leaf-powder is added to food (Oriakhi *et al*., 2022). Leaves are said to relieve stomach-ache, hernia, hematuria and food-poisoning. In Gabon a leaf-decoction is taken for dysentery and, as a strengthening food, powdered, dried stems cooked with groundnuts are given to women in pregnancy. A length of leafy stem screwed up into a ball is boiled in water which is drunk for dysentery in Sierra Leone. In Congo it is used as a vermifuge and purgative and with other plants for gastro-intestinal troubles. A snake-bite remedy which is held in great repute in Senegal is prepared from the leaves and roots together with other drug-plants (Diallo et al., 2019). As preparation requires 48 hours this is normally made in anticipation and held in stock by Casamance medicine-men. The preparation is taken both internally and externally. An alcoholic macerate of leafy-twigs in palm-wine is taken in Ivory Coast for asthma, and is considered to be also febrifugal. A root macerate is used for urethral discharges and is given as an enema to strengthen children with rickets. Leaves crushed with salt and pimento are taken in Ivory Coast as an aphrodisiac. Reports that the plant is piscicidal are probably erroneous. The plant is considered non-toxic by Ivorean medicine-men (Diallo et al., 2019). In Zaïre the young leaves are eaten as a vegetable. The leaves however have a quantity of flavones and mucilage and flavones are present in the root-bark. *Dilleniaceae* in general are rich in tannin. Investigation of the use of the stem in Nigerian folk-medicine for dermal infections has shown no action on Gram –ve organisms, and no anti-fungal action. The scientific classification of *Tetracera alnifolia* is presented in **Table 2**

TAXONOMIC RANK	CLASSIFICATION
KINGDOM	Plantae
DIVISION	Magnoliophyta
CLASS	Magnoliopsida
ORDER	Dilleniales
FAMILY	*Dilleniaceae*
GENUS	Tetracera
SPECIES	*Tetracera alnifolia*

Table 2: Taxonomical classification of *Tetracera alnifolia*

Morphologically, members of the genus *Tetracera* are often characterized by having leaves that are simple, alternate, and sometimes with an appearance similar to those of alder trees, which may be the origin of the species epithet "*alnifolia."* The flowers tend to be showy, with a range of colors that attract pollinators. They are usually arranged in clusters, and their structural details have been used to differentiate species within the genus. The fruit morphology also plays a role in the classification within the genus, often being a capsule or berry, which aids in seed dispersal.

2.6.3 Pharmacology

Before the discovery of antibiotics, infectious and parasitic diseases were the leading cause of death worldwide. They are now responsible for about 8% of deaths in developed countries but 50% of deaths in low-income countries (Murray et al., 2022). Within the context of increased poverty and malnutrition, combined with limited hygiene availability and access to high education,

infectious and protozoan diseases affect millions of people every year in low-income countries and currently represent the primary cause of mortality in the tropical zone (Santos et al., 2020).

In Guinea, according to data from the Ministry of Health, eight neglected tropical diseases (onchocerciasis, lymphatic filariasis, trachoma, schistosomiasis, soil-transmitted helminths, leprosy, human African trypanosomiasis and Buruli ulcer), in addition to malaria, were considered a public health problem (Cherif et al., 2023). Also, more than 50% of the population lives in highly rural areas where access to conventional healthcare facilities is rare. Taking into account these conditions, rural people in Guinea rely strongly on traditional herbal medicine to manage their healthcare, including to treat infectious diseases (Diallo et al., 2019).

Traditional healers in Nigeria have long utilized this plant for its medicinal properties, which modern phytochemical studies have begun to validate. The isolated compounds, including various flavonoids and coumarin derivatives, are now under scientific investigation for their potential antidiabetic, anti-inflammatory, and analgesic effects. (Gurja and Pal, 2023). In the folkloric medicine of Nigeria, T. alnifolius Wild is used in the treatment of various diseases and infections, including diabetes mellitus. Flavonoids, coumarin derivatives, and terpenoids are the main chemical constituents isolated from these plants' genera (Oriakhi *et al*., 2022). Isolation of phytochemicals such as kaempferol, kaempferol3-sulphate, quercetin, quercetin-3-O-galactopyranoside, quercetin-3-glucoronide, rhamnocitrin, rhamocitrin-3-sulphate, and procyanidin in the leaves of T. alnifolia has been reported. The leaves have been reported to possess anti-inflammatory, analgesic, and antituberculosis activities. (Oriakhi *et al*., 2022).

CHAPTER THREE

MATERIALS AND METHODS

3.1 MATERIALS

i. Chemicals and Reagents

Chemicals used in this research study include streptozotocin, ethanol, chloroform, and formaldehyde. The reagents used include physiological saline and creatinine reagent kit.

3.1.2 Apparatus

The following are the apparatus used during the research study centrifuge, glucometer (New Spring), freeze drier, spectrophotometer, electronic weighing balance, oral gavage, syringes (1mL, 2mL, 5mL and 10mL), pipette, spatula, dissecting kit, mortar and pestle and lancet. Other materials used include cotton wool, hand glove, universal containers, lithium heparin and plain blood bottles

3.2 METHODS

3.2.1 Plant collection

The roots and leaves of *Tetracera alnifolia* were sourced locally from Oyingbo Market, located in Lagos State, Nigeria. Following collection, the plant material was securely transported to the University of Benin, Edo State, Nigeria. To ensure proper authentication, the samples was taken to the Department of Plant Biology and Biotechnology, University of Benin, where it was identified and assigned an herbarium number (UBH-T405).

3.2.1 Plant extraction

The roots were and thoroughly washed with clean water to remove dirt and potential contaminants cut into smaller pieces. The cleaned plant material was then spread on a flat surface and left to air-dry at room temperature for a period of 14 days. After complete drying, the plant material was pulverized into a fine powder using a mechanical grinder to increase the surface area for extraction. 3kg of the pulverized root powder was soaked in ethanol a measurement of 15L (1:5) 72 hours with intermittent stirring to enhance extraction efficiency and prevent clumping. Ethanol was used in sufficient volume to ensure it remained approximately 2 cm above the level of the plant material.

Following the 72-hour extraction period, the mixture was carefully filtered using a double-layered muslin cloth to separate the plant residues from the extract. To ensure thorough extraction, the process was repeated twice, and the combined filtrates were subjected to solvent evaporation using a freeze dryer. The resultant dried extract, obtained in powdered form, was stored in an airtight container under refrigerated conditions until required for experimental use.

3.3 EXPERIMENTAL DESIGN

Wistar rats were obtained from the Pharmacology Laboratory of the University of Benin. Prior to commencement of the experiment, ethical approval was sought and obtained. The rats were acclimatized in the Animal House of the Department of Medical Biochemistry for a period of 14 days. During this period, they were maintained under standard laboratory conditions, including a 12-hour light/dark cycle, regulated room temperature, and adequate ventilation. The rats were fed a standard animal diet and had unrestricted access to food and water. Baseline body weights of all animals were recorded after the acclimatization period.

After the acclimatization period, fasting blood glucose levels of the rats were measured using a glucometer prior to induction of diabetes. Following induction, blood glucose levels were reassessed after seven days to confirm successful induction. A total of 36 male Wistar rats, each weighing between 180-200 g, were randomly divided into six experimental groups, with each group consisting of six animals:

- **Group 1:** Induced with diabetes and treated with 200 mg/kg body weight of *Tetracera alnifolia* ethanol extract, administered orally for 35 days. The rats were provided with standard rodent feed and water.
- **Group 2:** Induced with diabetes and treated with 500 mg/kg body weight of *Tetracera alnifolia* ethanol extract, administered orally for 35 days. The rats were maintained on standard rodent feed and water.
- **Group 3:** Induced with diabetes and treated with 800 mg/kg body weight of *Tetracera alnifolia* ethanol extract, administered orally for 35 days. The rats were maintained on standard rodent feed and water.
- **Group 4 (Standard Drug Control):** Induced with diabetes and treated with the standard antidiabetic drug glibenclamide for 35 days. The rats were provided with standard rodent feed and water.
- **Group 5 (Diabetic Control):** Induced with diabetes but did not receive any form of treatment throughout the study duration. The rats were maintained on standard rodent feed and water.

- **Group 6 (Normal Control):** Not induced with diabetes and did not receive any form of treatment. This group was maintained on standard rodent feed and water throughout the study.

3.4 DIABETES INDUCTION USING STREPTOZOTOCIN (STZ)

Diabetes was induced in the experimental animals using streptozotocin (STZ). STZ was procured in powdered form and dissolved in physiological saline to prepare a solution of appropriate concentration. Prior to STZ administration, the rats were fasted for 12 hours but were given free access to water to ensure optimal drug absorption. Each rat except the control group received an intraperitoneal injection of STZ at a dosage of 65 mg/kg body weight, administered using a sterile syringe. To confirm successful diabetes induction, blood samples were collected from the tail vein seven days post-STZ administration, and blood glucose levels were measured using a glucometer. Diabetes was considered successfully induced when fasting blood glucose levels exceeded 200 mg/dL (11 mmol/L).

Some animals exhibited physical signs of distress such as weight loss, fur thinning, and frequent urination. To ensure the welfare of the experimental animals, supportive care was provided, including close monitoring and humane handling.

3.5 PREPARATION OF THE STANDARD TREATMENT DRUG

To prepare the standard treatment, one tablet of Glibenclamide was first thoroughly crushed into a fine powder using a mortar and pestle. This powder was then transferred to a clean container and dissolved in 5 mL of distilled water. The mixture is stirred continuously until complete dissolution is achieved, ensuring uniformity of the solution. The final volume to be administered to the rats was adjusted based on their individual body weight, guaranteeing that each animal receives the appropriate dose.

3.6 COLLECTION OF BLOOD SAMPLES AND ORGAN ISOLATION

For the collection of blood samples and subsequent isolation of organs, each rat was first anesthetized using chloroform in a well-ventilated area with appropriate personal protective equipment. Once anesthesia was confirmed, a midline abdominal incision is performed to expose the aorta, facilitating the collection of blood. Following blood collection, the pancreas, liver, and kidneys are carefully dissected and removed using a sterile dissecting kit. The organs were immediately rinsed with physiological saline to remove any residual blood and debris. They were then fully immersed in a 10% formaldehyde solution for fixation, typically for 24 to 48 hours. Throughout the procedure, meticulous attention was paid to sample integrity, ethical handling of the animals, and adherence to established laboratory safety protocols. After the procedures were completed, the carcasses were disposed of in accordance with institutional guidelines, and all surgical tools were thoroughly sterilized to prevent cross-contamination.

CHAPTER FOUR

RESULTS

Table 4.1 Effect of Ethanol Extract of *Tetracera alnifolia* on Glutathione Peroxidase (GPx) Activity (unit/g tissue) in Liver of Streptozotocin-Induced Diabetic Wistar Rats

Group	**GPx Activity (Mean ± SEM)**
Healthy Control	3.69 ± 0.61^{a}
Diabetic Control	2.86 ± 0.38^{a}
200 mg/kg *T. alnifolia*	3.51 ± 0.48^{a}
500 mg/kg *T. alnifolia*	2.83 ± 0.42^{a}
800 mg/kg *T. alnifolia*	34.26 ± 0.62^{x}
5 mg/kg Glibenclamide	20.65 ± 0.01^{x}

Values are expressed as Mean ± SEM. Values sharing superscript 'a' are not significantly different from Healthy Control ($p > 0.05$). Values with superscript '^{x}' are significantly increased compared to Diabetic Control ($p < 0.05$).

Table 4.2: Effect of Ethanol Extract of *Tetracera alnifolia* on Glutathione Reductase (unit/g tissue) in Pancreas of Streptozotocin-Induced Diabetic Wistar Rats

Group	**Glutathione Reductase (Mean ± SEM)**
Healthy Control	**2.68 ± 0.11[a]**
Diabetic Control	**2.42 ± 0.22[a]**
200 mg/kg *T. alnifolia*	**5.74 ± 0.65[x]**
500 mg/kg *T. alnifolia*	**5.60 ± 0.01[x]**
800 mg/kg *T. alnifolia*	**8.41 ± 0.26[x]**
5 mg/kg Glibenclamide	**10.28 ± 1.28[x]**

Values are expressed as Mean ± SEM. Values sharing superscript 'a' are not significantly different from Healthy Control ($p > 0.05$). Values with superscript '[x]' are significantly increased compared to Diabetic Control ($p < 0.05$).

CHAPTER FIVE

DISCUSSION AND CONCLUSION

5.1 DISCUSSION

Diabetes mellitus induces marked oxidative stress in target organs, driven by chronic hyperglycemia mediated overproduction of reactive oxygen species (ROS) and depletion of endogenous antioxidants, contributing to cellular damage and enzyme dysfunction. In streptozotocin (STZ)–induced diabetic rats, oxidative stress manifests as decreased activities of key antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) alongside lowered tissue glutathione (GSH) levels, corroborating the link between hyperglycemia and redox imbalance.

From our study, GPx activity in liver tissue was profoundly restored by the ethanol extract of *T. alnifolia*, rising from 2.86 ± 0.38 units/g in diabetic controls to 34.26 ± 0.62 units/g at the highest dose (800 mg/kg) (Table 4.1). This dramatic increase parallels findings where plant extracts such as walnut leaf and olive leaf significantly enhanced GPx activity in STZ models, demonstrating dose-dependent antioxidant effects that mitigate lipid peroxidation and support cellular redox homeostasis. Glutathione reductase (GR) activity in pancreatic tissue followed a comparable trend, with extract-treated groups exhibiting a stepwise increase from 2.42 ± 0.22 units/g (diabetic controls) to 8.41 ± 0.26 units/g at 800 mg/kg and 10.28 ± 1.28 units/g with glibenclamide (Table 4.2). Enhanced GR activity is critical for regenerating reduced GSH from its oxidized form (GSSG), sustaining the intracellular pool of this master antioxidant. Such elevations mirror observations with vitamin E supplementation in STZ rats, where GR and GPx activities were restored alongside improvements in renal and hepatic function parameters.

The dose-dependency observed suggests that bioactive constituents' likely flavonoids and terpenoids act via transcriptional upregulation of antioxidant enzymes (e.g., via Nrf2 pathway activation) and direct free-radical scavenging, as described in other botanical studies on STZ models (e.g., *Mimosa pudica*, purple potato). By replenishing GPx and GR activities, *T. alnifolia* extract not only counters oxidative insults but also interrupts the vicious cycle of ROS-induced cellular injury and further antioxidant depletion. Restoration of antioxidant enzyme activities is expected to translate into histopathological protection. In STZ-diabetes, oxidative damage leads to hepatocellular vacuolation, pancreatic β-cell apoptosis, and renal glomerular sclerosis; reversal of redox imbalance by botanical antioxidants has been shown to preserve tissue architecture and reduce inflammatory infiltrates in these organs. Although histology was not detailed here, the substantial biochemical recovery observed indicates that *T. alnifolia* extract likely mitigates such pathological lesions.

Similarly, scholarly work was done by Saeedi *et al.,* (2019) on *Tetracera* species, which focused chiefly on hypoglycemic effects, our findings extend the therapeutic profile to include robust antioxidant enzyme modulation and potential improvement in microenvironmental redox balance. This multifaceted action positions *T. alnifolia* as a promising complementary agent for diabetes management, targeting both metabolic control and prevention of oxidative-stress–related tissue injury.

Overall, the ethanol extract of *Tetracera alnifolia* exhibits potent hepatopancreatic antioxidant effects in STZ-induced diabetes, significantly elevating GPx and GR activities (Tables 3 and 4). By restoring these crucial enzymes, the extract may prevent progression of diabetic complications. Future work should include detailed histopathological assessment and exploration of molecular

signaling pathways (e.g., Nrf2/ARE, NF-κB) to fully elucidate the mechanisms underlying these protective effects.

5.2 CONCLUSION

Diabetes mellitus, defined by chronic elevated blood glucose, induces profound metabolic dysregulation and oxidative stress, culminating in extensive tissue injury and persistent health complications. This study demonstrated that the ethanol extract of *Tetracera alnifolia* effectively reduces fasting blood glucose, enhances reduced glutathione activity, and stabilizes serum potassium in streptozotocin-induced diabetic Wistar rats, mitigating key drivers of diabetic pathology. These biochemical improvements are likely to translate into reduced tissue damage and improved metabolic homeostasis, supporting the traditional use of *T. alnifolia* in diabetes management. Overall, our results provide a strong basis for further histopathological and molecular investigations to fully elucidate the mechanisms by which *T. alnifolia* confers its protective effects and to explore its potential as a complementary therapeutic agent in diabetes treatment.

REFERENCES

Abdulfatah, H. F. (2022). Non-enzymatic antioxidants in stressed plants: A review. *J. Univ. Anbar Pure Sci*, 16(4):25-37.

Ahamed, B. S., Arya, M. S., Sangeetha, S. K. B., and Auxilia Osvin, N. V. (2022). Diabetes mellitus disease prediction and type classification involving predictive modeling using machine learning techniques and classifiers. *Applied Computational Intelligence and Soft Computing*, 2(1):78-99.

Ahmed, O. M., and Mohammed, M. T. (2020). Oxidative stress: The role of reactive oxygen species (ROS) and antioxidants in human diseases. *Plant Arch*, 20(2):4089-4095.

Ajao, A. A. N., and Sadgrove, N. J. (2024). Cosmetopoeia of African Plants in Hair Treatment and Care: Topical Nutrition and the Antidiabetic Connection? *Diversity*, 16(2):96.

Alam, M. M. (2021). *Prevalence of Type 2 Diabetes Mellitus complications in human* (Doctoral dissertation, Chattogram Veterinary and Animal| Sciences University). 7(2):10-83.

Ali, A., Kumar, M., Srivastava, N., Khan, M. M., and Khan, M. A. (2023). Free radicals and diabetes mellitus. *Int. J. Pharm. Sci. Med*, 8(4):1-19.

Al-Musawi, J. F (2020). Evaluation of some Herbal Agents in the treatment of Diabetes in Comparison to Insulin. Pathophysiology of diabetes: An overview. *Avicenna journal of medicine*, 10(4):174-188.

Alser, M., Naja, K., and Elrayess, M. A. (2024). Mechanisms of body fat distribution and gluteal-femoral fat protection against metabolic disorders. *Frontiers in Nutrition*, 11(3):68-96.

Anlar, H. G. (2020). Cinnamic acid as a dietary antioxidant in diabetes treatment. In *Diabetes*, 5(2):10-83.

Anwar, S., Khan, S., Almatroudi, A., Khan, A. A., Alsahli, M. A., Almatroodi, S. A., and Rahmani, A. H. (2021). A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds. *Molecular Biology Reports*, 48(4):787-805.

Anwar, S., Khan, S., Almatroudi, A., Khan, A. A., Alsahli, M. A., Almatroodi, S. A., and Rahmani, A. H. (2021). A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds. *Molecular Biology Reports*, 48(5):787-805.

Awuchi, C. G. (2020). The biochemistry, toxicology, and Uses of the acologically active phytochemicals: Alkaloids, terpenes, polyphenols, and glycosides. *Merit Research Journals*, 5(1):6-21.

Baldé, M. A. (2021). *Phytochemical, antimicrobial and antiplasmodial investigations on Guinean plant species* (Doctoral dissertation, University of Antwerp), 7(2):107-84.

Banday, M. Z., Sameer, A. S., and Nissar, S. (2020). Pathophysiology of diabetes: An overview. *Avicenna journal of medicine*, 10(04):174-188.

Bathaie, S. Z., Sedghgoo, F., Jafarnejad, A., Farzami, B., and Khayatian, M. (2018). Spectroscopic studies of STZ-induced methylated-DNA in both in vivo and in vitro conditions. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 71(3):803-808.

Berger, C., and Zdzieblo, D. (2020). Glucose transporters in pancreatic islets. *Pflügers Archiv-European Journal of Physiology*, 472(9):1249-1272.

Bhatti, J. S., Sehrawat, A., Mishra, J., Sidhu, I. S., Navik, U., Khullar, N., ... and Reddy, P. H. (2022). Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. *Free Radical Biology and Medicine*, 184(6):114-134.

Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., and Omelka, R. (2021). Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. *Pharmaceuticals*, 14(8): 806.

Chukwuma, C. I., Matsabisa, M. G., Ibrahim, M. A., Erukainure, O. L., Chabalala, M. H., and Islam, M. S. (2019). Medicinal plants with concomitant anti-diabetic and anti-hypertensive effects as potential sources of dual acting therapies against diabetes and hypertension: A review. *Journal of ethnopharmacology*, 23(5):329-360.

da Silva Rosa, S. C., Nayak, N., Caymo, A. M., and Gordon, J. W. (2020). Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. *Physiological reports*, 8(19):14-67.

Deligiorgi, M. V., and Trafalis, D. T. (2023). A concerted vision to advance the knowledge of diabetes mellitus related to immune checkpoint inhibitors. *International Journal of Molecular Sciences*, 24(8): 76-80.

Di Meo, S., and Venditti, P. (2020). Evolution of the knowledge of free radicals and other oxidants. *Oxidative medicine and cellular longevity*, 2(1):98-276.

Diab, R. A. H., Fares, M., Abedi-Valugerdi, M., Kumagai-Braesch, M., Holgersson, J., and Hassan, M. (2023). Immunotoxicological effects of streptozotocin and alloxan: in vitro and in vivo studies. *Immunology Letters*, 163(2):193-198.

García, L. F. (2020). Immune response, inflammation, and the clinical spectrum of COVID-19. *Frontiers in immunology*, 11(2):14-41.

Genuth, S. M., Palmer, J. P., and Nathan, D. M. (2021). Classification and diagnosis of diabetes. 17(2):17-84.

Goodarzi, M. O., and Rotter, J. I. (2020). Genetics insights in the relationship between type 2 diabetes and coronary heart disease. *Circulation research*, 126(11):1526-1548.

Gurjar, V. K., and Pal, D. (2023). Classification of Medicinal Plants Showing Anti-Viral Activity, Classified by Family and Viral Infection Types. In *Anti-viral metabolites from medicinal plants*, 4(5):7-195

Halim, M., and Halim, A. (2019). The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). *Diabetes and metabolic syndrome: clinical research and reviews*, 13(2):1165-1172.

Horn, J. W. (2020). *The phylogenetics and structural botany of Dilleniaceae and Hibbertia Andrews*, 157(2):107-843.

Janssen, J. A. (2021). Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. *International journal of molecular sciences*, *22*(15):77-97.

Jomova, K., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., and Valko, M. (2024). Several lines of antioxidant defense against oxidative stress: Antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. *Archives of Toxicology*, 98(5):1323-1367.

Khunti, K., Del Prato, S., Mathieu, C., Kahn, S. E., Gabbay, R. A., and Buse, J. B. (2021). COVID-19, hyperglycemia, and new-onset diabetes. *Diabetes care*, 44(12):2645-2655.

Kivimäki, M., Bartolomucci, A., and Kawachi, I. (2023). The multiple roles of life stress in metabolic disorders. *Nature Reviews Endocrinology*, 19(1):10-27.

Lawson, S. (2020). Introduction to Vitamin C and Cancer Clinical Studies: A Historical Perspective. In *Cancer and Vitamin C*, 157(2):107-843.

Le Pard, A. M. (2022). *Characteristics and Signs in Nontraditional Glycemia Atypical Insulin Resistance-Type 2 Diabetes* (Doctoral dissertation, University of Colorado Denver, Anschutz Medical Campus).

Leyane, T. S., Jere, S. W., and Houreld, N. N. (2022). Oxidative stress in ageing and chronic degenerative pathologies: molecular mechanisms involved in counteracting oxidative stress and chronic inflammation. *International journal of molecular sciences*, 23(13):72-73.

Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., and Xu, H. (2022). Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal transduction and targeted therapy*, 7(1):216.

Lin, X., Xu, Y., Pan, X., Xu, J., Ding, Y., Sun, X., ... and Shan, P. F. (2020). Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. *Scientific reports*, 10(1):1-11.

Luo, Y., and Wang, S. (2022). Urban living and chronic diseases in the presence of economic growth: Evidence from a long-term study in southeastern China. *Frontiers in Public Health*, 101(4):24-43.

Matough, F. A., Budin, S. B., Hamid, Z. A., Alwahaibi, N., and Mohamed, J. (2022). The role of oxidative stress and antioxidants in diabetic complications. *Sultan Qaboos university medical journal*, 12(1):5.

Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., ... and Eknoyan, G. (2023). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving Global Outcomes (KDIGO). *Kidney international*, 69(11):1945-1953.

Murtaza, G., Riaz, S., Zafar, M., Ahsan Raza, M., Kaleem, I., Imran, H., ... and Bashir, S. (2024). Examining the growing challenge: Prevalence of diabetes in young adults. *Medicine International*, 5(1):2-4.

Nathan, D. M., and Lachin, J. M. (2024). History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes. *Diabetes care*, 47(9):1511-1517.

Oriakhi, K., Ibeji, C. U., Essien, E. E., Eluehike, N., Orumwensodia, K., Uadia, P., and Choudhary, I. M. (2022). In vitro and computational studies on the antiglycation activity of compounds isolated from antidiabetic Tetracera alnifolia stem bark. *Journal of Biomolecular Structure and Dynamics*, 40(20):9742-9751.

Papachristoforou, E., Lambadiari, V., Maratou, E., and Makrilakis, K. (2020). Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. *Journal of diabetes research*, 2(1):48-75.

Rajput, V. D., Harish, Singh, R. K., Verma, K. K., Sharma, L., Quiroz-Figueroa, F. R., ... and Mandzhieva, S. (2021). Recent developments in enzymatic antioxidant defence mechanism in plants with special reference to abiotic stress. *Biology*, 10(4):2-7.

Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., ... and Suárez-Almazor, M. E. (2020). Immune-related adverse events of checkpoint inhibitors. *Nature reviews Disease primers*, 6(1):38-40.

Roy, S., Pokharel, P., and Piganelli, J. D. (2024). Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes. *Molecular Metabolism*, 12(4):101-998.

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., ... and IDF Diabetes Atlas Committee. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes research and clinical practice*, 157(2):107-843.

Saroy, K., and Garg, N. (2021). Role of non-enzymatic antioxidant defense mechanisms in imparting heavy metal, salt, water and temperature stress tolerance in plants. In *Organic Solutes, Oxidative Stress, and Antioxidant Enzymes Under Abiotic Stressors*, 5(2):7-8.

Seigler, D. S., Friesen, J. B., Bisson, J., Graham, J. G., Bedran-Russo, A., McAlpine, J. B., and Pauli, G. F. (2021). Do certain flavonoid IMPS have a vital function? *Frontiers in Nutrition*, 8(7):62-73.

Shaparov, M. G., Gudkov, S. V., Lankin, V. Z., and Novoselov, V. I. (2021). Role of glutathione peroxidases and peroxiredoxins in free radical-induced pathologies. *Biochemistry (Moscow)*, 86(4):1418-1433.

Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., ... and Sharifi-Rad, J. (2020). Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. *Frontiers in physiology*, 11(5):52-55.

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., ... and Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes research and clinical practice*, 183(5):109-119.

Szkudelski, T. (2021). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. *Physiological research*, 50(6):537-546.

Taghavi, F., and Moosavi-Movahedi, A. A. (2019). Free radicals, diabetes, and its complexities. *Plant and Human Health, Volume 2: Phytochemistry and Molecular Aspects*, 4(2):1-41.

Tareen, R. S., and Tareen, K. (2022). Psychosocial aspects of diabetes management: dilemma of diabetes distress. *Translational pediatrics*, 6(4):3-8.

Tatovic, D., Narendran, P., and Dayan, C. M. (2023). A perspective on treating type 1 diabetes mellitus before insulin is needed. *Nature Reviews Endocrinology*, 19(6):361-370.

Thakur, P., Kumar, A., and Kumar, A. (2018). Targeting oxidative stress through antioxidants in diabetes mellitus. *Journal of drug targeting*, 26(9):766-776.

Vallon, V. (2020). Glucose transporters in the kidney in health and disease. *Pflügers Archiv-European Journal of Physiology*, 472(9):1345-1370.

Wajchenberg, B. L. (2007). β-cell failure in diabetes and preservation by clinical treatment. *Endocrine reviews*, 28(2):187-218.

Welsch, S. (2023). *Characterization and identification of atypical diabetes in pediatric patients* (Doctoral dissertation, UCL-Université Catholique de Louvain). 10(4):5-11.

Yameny, A. A. (2024). Diabetes Mellitus Overview 2024. *Journal of Bioscience and Applied Research*, 10(3):641-645.

Zhang, C., Wang, X., Du, J., Gu, Z., and Zhao, Y. (2021). Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment. *Advanced Science*, 8(3):20-27.

Zhao, X., An, X., Yang, C., Sun, W., Ji, H., and Lian, F. (2023). The crucial role and mechanism of insulin resistance in metabolic disease. *Frontiers in endocrinology*, 14(11):49-59.

Zhu, B. T. (2022). Pathogenic mechanism of autoimmune diabetes mellitus in humans: potential role of streptozotocin-induced selective autoimmunity against human islet β-cells. *Cells*, 11(3):4-9.

Zhu, B., and Qu, S. (2022). The relationship between diabetes mellitus and cancers and its underlying mechanisms. *Frontiers in Endocrinology*, 13(8):40-95.